Modeling the Cost-effectiveness of Rituximab Use Compared to Tumor Necrosis Factor Inhibitors (anti-TNF) Agents as a Second-line Therapy in Patients with Rheumatoid Arthritis (RA) in Quebec, Canada Using RHUMADATA Registry Data

被引：0
|
作者：
Lopatina, Elena [1 ]
Choquette, Denis [2 ]
Coupal, Louis [2 ]
Marshall, Deborah [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Inst Rhumatol Montreal, Montreal, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
60
引用
收藏
页码：882 / 883
页数：2
相关论文
共 31 条
  • [1] MODELING THE COST-EFFECTIVENESS OF RITUXIMAB USE COMPARED TO TUMOR NECROSIS FACTOR INHIBITORS (ANTI-TNF) AGENTS AS A SECOND-LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN QUEBEC, CANADA USING RHUMADATA REGISTRY DATA
    Lopatina, E.
    Marshall, D. A.
    Coupal, L.
    Choquette, D.
    VALUE IN HEALTH, 2017, 20 (05) : A147 - A147
  • [2] Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the RHUMADATA® Clinical Database and Registry
    Choquette, Denis
    Bessette, Louis
    Fortin, Isabelle
    Haraoui, Boulos
    Pelletier, Jean-Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Massicotte, Frederic
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1298 - 1298
  • [3] Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry.
    Choquette, Denis
    Raynauld, Jean-Pierre
    Pelletier, Jean Pierre
    Haraoui, Boulos
    Bessette, Louis
    Villeneuve, Edith
    Remillard, Marie-Anais
    Fortin, Isabelle
    Sauvageau, Diane
    Coupal, Louis
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S676 - S676
  • [4] USE OF RITUXIMAB COMPARED TO ANTI-TNF AGENTS AS SECOND AND THIRD LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A REPORT FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY
    Choquette, D.
    Raynauld, J. -P.
    Bessette, L.
    Fortin, I.
    Haraoui, B.
    Pelletier, J. P.
    Remillard, M. -A.
    Sauvageau, D.
    Villeneuve, E.
    Coupal, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 881 - 881
  • [5] Better Retention Rate of Rituximab Vs Anti-Tnf Agents As Second Line therapy in RA Patients Failing a First Anti-Tnf Agents: Results From the Rhumadata® Registry
    Choquette, D.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S859 - S859
  • [6] Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
    Huoponen, Saara
    Aaltonen, Kalle J.
    Viikinkoski, Jaana
    Rutanen, Jarno
    Relas, Heikki
    Taimen, Kirsi
    Puolakka, Kari
    Nordstrom, Dan
    Blom, Marja
    PLOS ONE, 2019, 14 (07):
  • [7] Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis
    Lopatina, Elena
    Marshall, Deborah A.
    Coupal, Louis
    Le Lorier, Jacques
    Choquette, Denis
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 157 - 166
  • [8] Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
    Choquette, Denis
    Bessette, Louis
    Haraoui, Boulos
    Massicotte, Frederic
    Pelletier, Jean-Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    Brown, Jacques
    Turcotte, Angele
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [9] Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A 6 Year Follow-Up Report from the Rhumadata Clinical Database and Registry
    Choquette, Denis
    Bessette, Louis
    Brown, Jacques
    Haraoui, Boulos
    Massicotte, Frederic
    Pelletier, Jean-Pierre
    Raynauld, Jean-Pierre
    Remillard, Marie-Anais
    Sauvageau, Diane
    Villeneuve, Edith
    Coupal, Louis
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1212 - 1213
  • [10] A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS
    Huoponen, S.
    Aaltonen, K. J.
    Joensuu, J. T.
    Rutanen, J.
    Relas, H.
    Taimen, K.
    Puolakka, K.
    Sokka, T.
    Nordstrom, D.
    Blom, M.
    VALUE IN HEALTH, 2016, 19 (07) : A538 - A538
1234